Piper Sandler Reiterates Overweight on PROCEPT BioRobotics, Maintains $75 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Matt O'Brien has reiterated an Overweight rating on PROCEPT BioRobotics (NASDAQ:PRCT) and maintained a price target of $75.
October 08, 2024 | 2:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler has reiterated an Overweight rating on PROCEPT BioRobotics, maintaining a $75 price target, indicating confidence in the company's potential for growth.
The reiteration of an Overweight rating and maintenance of a $75 price target by Piper Sandler suggests a positive outlook for PROCEPT BioRobotics. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100